Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

Investigational c-Met inhibitor shows early promise in NSCLC

A first-in-class drug that inhibits c-Met, a receptor tyrosine kinase, has demonstrated good tolerability when combined with erlotinib in the treatment of Japanese patients with advanced/metastatic non-small-cell lung cancer.

3 Dec 2013

New report on global prevalence of anemia

Despite increasing efforts to diagnose and treat anemia worldwide, there remains a surprisingly large global burden of the disease, particularly among young children and women, according to a new report on trends in anemia between 1990 and 2010.

3 Dec 2013

Scientists identify new approach to fight malaria parasites

Using advanced methodologies that pit drug compounds against specific types of malaria parasite cells, an international team of scientists, including researchers at the University of California, San Diego School of Medicine and the Genomics Institute of the Novartis Research Foundation, have identified a potential new weapon and approach for attacking the parasites that cause malaria.

28 Nov 2013

Dysregulation of epigenetic marks may play role in chronic kidney disease, shows study

The research of physician-scientist Katalin Susztak, MD, PhD, associate professor of Medicine in the Renal Electrolyte and Hypertension Division, at the Perelman School of Medicine, University of Pennsylvania, strives to understand the molecular roots and genetic predisposition of chronic kidney disease.

26 Nov 2013

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

25 Nov 2013

U-M study explores exercise-induced iron-deficiency anemia in female runners

When Kaitlyn Patterson's fatigue progressed to hyperventilating even during slow runs, and then forced her to quit high school distance running for the season, she knew something was very wrong. Patterson had exercise-induced iron-deficiency anemia, a common, perplexing problem among elite female athletes, especially endurance runners. Later, as a University of Michigan sophomore, she was so interested in the topic that she applied for an undergraduate research position in the lab of Peter Bodary, U-M clinical assistant professor of movement science and health & fitness.

22 Nov 2013

New paper highlights correlations between changes in natural systems and potential health outcomes

A new paper from members of the HEAL (Health & Ecosystems: Analysis of Linkages) consortium delineates a new branch of environmental health that focuses on the public health risks of human-caused changes to Earth's natural systems.

20 Nov 2013

Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.

20 Nov 2013

Researchers discover association between RDW levels and depression in heart disease patients

Researchers at the Intermountain Medical Center Heart Institute have discovered a link between elevated red cell distribution width levels and depression in patients being treated for heart disease.

19 Nov 2013

Segregating household sleeping arrangements can help prevent malaria spread

Better malaria control might come from segregating household sleeping arrangements, according to a new study co-authored by a University of Guelph professor.

19 Nov 2013

European Commission grants marketing authorization for Bayer HealthCare's Xofigo injection

Bayer HealthCare announced today that the European Commission has granted marketing authorization for Xofigo (radium Ra 223 dichloride) solution for injection for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. This decision follows a positive recommendation from the European Committee for Medicinal Products for Human Use in September of this year.

15 Nov 2013

Malaria No More honors Hillary Rodham Clinton with Global Leadership Award

In an inspiring awards dinner Monday night, Malaria No More presented Former United States Secretary of State and Former Senator from New York Hillary Rodham Clinton with the Global Leadership Award.

15 Nov 2013

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer.

13 Nov 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

13 Nov 2013

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.

12 Nov 2013

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

IVIG is a hugely successful biological with FDA approval for treating idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barré syndrome, Graves ophthalmopathy and numerous polyneuropathies.

11 Nov 2013

Multiple pregnancies: A major public health concern worldwide

Multiple pregnancies are a major public health concern in the United States and the rest of the world due to the significantly higher health risks for both mothers and infants, as well as the impact on healthcare costs.

11 Nov 2013

NIDDK director to receive Outstanding Achievement Award from NKF

The National Kidney Foundation will honor Dr. Griffin P. Rodgers, Director of the National Institute of Diabetes and Digestive and Kidney Diseases, one of the National Institutes of Health, for his commitment to bettering the lives of patients and raising awareness of chronic kidney disease.

7 Nov 2013

DaVita HealthCare announces results for third quarter 2013

DaVita HealthCare Partners Inc. (NYSE: DVA) today announced results for the quarter ended September 30, 2013. Adjusted income from continuing operations attributable to DaVita HealthCare Partners Inc. for the three and nine months ended September 30, 2013 was $211.0 million and $605.3 million, or $0.98 and $2.82 per share, respectively, excluding a loss contingency reserve. In addition, adjusted income from continuing operations attributable to DaVita HealthCare Partners Inc. for the nine months ended September 30, 2013 excluded a contingent earn-out obligation adjustment. Income from continuing operations attributable to DaVita HealthCare Partners Inc. for the three and nine months ended September 30, 2013 including these items was $136.6 million and $407.9 million, or $0.64 per share and $1.90 per share, respectively.

6 Nov 2013